派林生物：控股股东东胜帮英豪与中国生物签署补充协议 转让交易最终截止日延长至2026年6月

Core Viewpoint - The announcement indicates that the share transfer agreement between the controlling shareholder, Shengbang Yinghao, and China Biotech has been extended until June 30, 2026, allowing for the transfer of 199,878,656 shares, which represents 21.03% of the company's total equity [1] Group 1 - The share transfer agreement extension allows China Biotech to become the controlling shareholder of the company [1] - China Biotech has already paid 30% of the transfer fee and submitted for state-owned assets and antitrust review [1] - The completion of the transaction is subject to compliance confirmation from the Shenzhen Stock Exchange and registration with the China Securities Depository and Clearing Corporation, indicating uncertainty in the implementation outcome [1]